BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin Pharmacokinet 2015;54:1107-23. [PMID: 26123705 DOI: 10.1007/s40262-015-0296-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Doshi S, Wang H, Chow V. Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2021.11.016] [Reference Citation Analysis]
2 l’Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018;77:484-7. [DOI: 10.1136/annrheumdis-2017-211781] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
3 Rekeland IG, Fluge Ø, Alme K, Risa K, Sørland K, Mella O, de Vries A, Schjøtt J. Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clin Ther 2019;41:806-14. [PMID: 30502905 DOI: 10.1016/j.clinthera.2018.10.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol 2021. [PMID: 33416999 DOI: 10.1007/s00415-020-10362-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
5 Jiménez Morales A, Maldonado-Montoro M, Martínez de la Plata JE, Pérez Ramírez C, Daddaoua A, Alarcón Payer C, Expósito Ruiz M, García Collado C. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis. J Clin Pharmacol 2019;59:517-31. [PMID: 30457672 DOI: 10.1002/jcph.1341] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016;55:2191-9. [PMID: 27651526 DOI: 10.1093/rheumatology/kew326] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
7 den Broeder AA, van Herwaarden N, van den Bemt BJF. Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Curr Opin Rheumatol 2018;30:266-75. [PMID: 29389829 DOI: 10.1097/BOR.0000000000000487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Wang X, Du W, Zhang X, Li P. The Influence of Different Disease States on Rituximab Pharmacokinetics. Curr Drug Metab 2020;21:938-46. [PMID: 32682367 DOI: 10.2174/1389200221666200719004035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Thomas PWA, Chin PKL, Barclay ML. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Intern Med J 2021;51:341-7. [PMID: 32043746 DOI: 10.1111/imj.14778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol 2020;11:312. [PMID: 32174918 DOI: 10.3389/fimmu.2020.00312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Bensalem A, Ternant D. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clin Pharmacokinet 2020;59:857-74. [DOI: 10.1007/s40262-020-00874-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
12 Johnson KW, Neale A, Gordon A, Roessig J, Bezwada P, Vukelich S, Goldfine I, Rubin P. Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers. J Clin Endocrinol Metab 2017;102:3021-8. [PMID: 28605468 DOI: 10.1210/jc.2017-00822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 Pedersen ME, Østergaard J, Glintborg B, Hetland ML, Jensen H. Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis. Sci Rep 2022;12:4670. [PMID: 35304547 DOI: 10.1038/s41598-022-08682-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Levy RA, Guzman R, Castañeda-Hernández G, Martinez-Vazquez M, Damian G, Cara C. Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. Immunotherapy 2016;8:1427-36. [PMID: 27737604 DOI: 10.2217/imt-2016-0067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ternant D, Chhun S. [Pharmacokinetic variability of therapeutic antibodies]. Med Sci (Paris) 2019;35:1130-6. [PMID: 31903927 DOI: 10.1051/medsci/2019210] [Reference Citation Analysis]
16 Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. Br J Clin Pharmacol 2019;85:2264-79. [PMID: 31315147 DOI: 10.1111/bcp.14062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Scherger S, Henao-Martínez A, Franco-Paredes C, Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. Med Hypotheses 2020;144:110053. [PMID: 32758889 DOI: 10.1016/j.mehy.2020.110053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
18 Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-111. [PMID: 29042821 DOI: 10.2147/cpaa.s138414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
19 Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-angoulvant T, Pascual-salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Therapeutic Drug Monitoring 2017;39:339-43. [DOI: 10.1097/ftd.0000000000000410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
20 Nelson MT, Slocik JM, Romer EJ, Mankus CI, Agans RT, Naik RR, Hussain SM. Examining cellular responses to reconstituted antibody protein liquids. Sci Rep 2021;11:17066. [PMID: 34426606 DOI: 10.1038/s41598-021-96375-8] [Reference Citation Analysis]
21 Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs 2016;8:1407-16. [PMID: 27589009 DOI: 10.1080/19420862.2016.1216741] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
22 Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS One 2016;11:e0162752. [PMID: 27806057 DOI: 10.1371/journal.pone.0162752] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
23 Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci 2020;13:743-51. [PMID: 32100960 DOI: 10.1111/cts.12760] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Li H, Zhu H, Xu L, Xue J, Zhao Z, Zhong H, Li R, Su Y. The characteristics and its contributing factors of refractory rheumatoid arthritis, view of the rheumatologists of China: results of a nationwide cross-sectional survey. Clin Rheumatol 2021. [PMID: 33942201 DOI: 10.1007/s10067-021-05687-7] [Reference Citation Analysis]
25 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 26.5] [Reference Citation Analysis]
26 Truffot A, Gautier-Veyret E, Baillet A, Jourdil JF, Stanke-Labesque F, Gottenberg JE. Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundam Clin Pharmacol 2021;35:1090-9. [PMID: 33638167 DOI: 10.1111/fcp.12662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Law-Wan J, Sparfel MA, Derolez S, Azzopardi N, Goupille P, Detert J, Mulleman D, Bejan-Angoulvant T. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open 2021;7:e001882. [PMID: 34789535 DOI: 10.1136/rmdopen-2021-001882] [Reference Citation Analysis]
28 Balevic SJ, Sagcal-Gironella ACP. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. Rheum Dis Clin North Am 2022;48:305-30. [PMID: 34798954 DOI: 10.1016/j.rdc.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 4 Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017;10:899-910. [PMID: 28490202 DOI: 10.1080/17512433.2017.1329009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
30 Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler 2020;26:137-52. [PMID: 31237800 DOI: 10.1177/1352458519858604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
31 Maranini B, Bortoluzzi A, Silvagni E, Govoni M. Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis. JPM 2022;12:499. [DOI: 10.3390/jpm12030499] [Reference Citation Analysis]
32 Van Herwaarden N, Van Den Bemt BJF, Wientjes MHM, Kramers C, Den Broeder AA. Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opin Drug Metab Toxicol 2017;13:843-57. [PMID: 28686523 DOI: 10.1080/17425255.2017.1353602] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
33 Bastida C, Huitema ADR, l'Ami MJ, Ruiz-Esquide V, Wolbink GJ, Sanmartí R, Soy D. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. Eur J Clin Pharmacol 2020;76:1417-25. [PMID: 32514745 DOI: 10.1007/s00228-020-02925-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford) 2020;59:3917-26. [PMID: 32710102 DOI: 10.1093/rheumatology/keaa291] [Reference Citation Analysis]
35 Le Tilly O, Bejan-Angoulvant T, Paintaud G, Ternant D. Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications. Br J Clin Pharmacol 2021;87:1594-5. [PMID: 33269471 DOI: 10.1111/bcp.14554] [Reference Citation Analysis]
36 Marra F, Smolders EJ, El-Sherif O, Boyle A, Davidson K, Sommerville AJ, Marzolini C, Siccardi M, Burger D, Gibbons S, Khoo S, Back D. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs R D 2021;21:9-27. [PMID: 33336316 DOI: 10.1007/s40268-020-00333-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld KH. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol 2020;86:2274-85. [PMID: 32363771 DOI: 10.1111/bcp.14330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Bastida C, Soy D, Ruiz-Esquide V, Sanmartí R, Huitema ADR. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components. Br J Clin Pharmacol 2019;85:1710-8. [PMID: 30958574 DOI: 10.1111/bcp.13954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, Huitema ADR, Soy D. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol 2018;84:716-25. [PMID: 29314183 DOI: 10.1111/bcp.13500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
40 Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin CM. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clin Pharmacokinet 2017;56:107-25. [PMID: 27384528 DOI: 10.1007/s40262-016-0426-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ellingsgaard H, Seelig E, Timper K, Coslovsky M, Soederlund L, Lyngbaek MP, Wewer Albrechtsen NJ, Schmidt-Trucksäss A, Hanssen H, Frey WO, Karstoft K, Pedersen BK, Böni-Schnetzler M, Donath MY. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia 2020;63:362-73. [PMID: 31796986 DOI: 10.1007/s00125-019-05045-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
42 Geurts-Voerman GE, Verhoef LM, van den Bemt BJF, den Broeder AA. The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence. BMC Rheumatol 2020;4:37. [PMID: 32743343 DOI: 10.1186/s41927-020-00130-x] [Reference Citation Analysis]
43 Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Mélet J, Paintaud G, Ternant D. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 2017;83:1773-81. [PMID: 28230269 DOI: 10.1111/bcp.13270] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
44 Passot C, Pouw MF, Mulleman D, Bejan-angoulvant T, Paintaud G, Dreesen E, Ternant D. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic–Pharmacodynamic Modeling. Therapeutic Drug Monitoring 2017;39:322-6. [DOI: 10.1097/ftd.0000000000000389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
45 Tang M, Meng J, Wang J. New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators. Int J Mol Sci 2019;21:E262. [PMID: 31906003 DOI: 10.3390/ijms21010262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
46 Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Gouilleux-Gruart V, Cornec D, Specks U, Ternant D. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clin Pharmacokinet 2020;59:519-30. [PMID: 31586310 DOI: 10.1007/s40262-019-00826-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, Sengar M, Nair R, Menon H. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2016;78:353-9. [PMID: 27329361 DOI: 10.1007/s00280-016-3083-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
48 Iwamoto N, Takanashi M, Yokoyama K, Yonezawa A, Denda M, Hashimoto M, Tanaka M, Ito H, Matsuura M, Yamamoto S, Honzawa Y, Matsubara K, Shimada T. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS. J Immunol Methods 2019;472:44-54. [PMID: 31201793 DOI: 10.1016/j.jim.2019.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Bastida C, Ruíz V, Pascal M, Yagüe J, Sanmartí R, Soy D. Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis? Br J Clin Pharmacol 2017;83:962-75. [PMID: 27990682 DOI: 10.1111/bcp.13192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Reijers JAA, Moerland M, Burggraaf J. Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation. Clin Pharmacokinet 2017;56:1081-9. [PMID: 28000101 DOI: 10.1007/s40262-016-0497-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
51 Bertholee D, Maring JG, van Kuilenburg AB. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet 2017;56:317-37. [PMID: 27641154 DOI: 10.1007/s40262-016-0450-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
52 Moore LS, Rosenthal EL, de Boer E, Prince AC, Patel N, Richman JM, Morlandt AB, Carroll WR, Zinn KR, Warram JM. Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation. Mol Imaging Biol 2017;19:610-6. [PMID: 27830425 DOI: 10.1007/s11307-016-1022-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
53 Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, Cascino MD, Brunetta P, Murray DL, Snyder MR, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Barnidge DR, Specks U. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford) 2018;57:639-50. [PMID: 29340623 DOI: 10.1093/rheumatology/kex484] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
54 Liu S, Kiyoi T, Ishida M, Mogi M. Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells. Front Pharmacol 2020;11:1004. [PMID: 32719606 DOI: 10.3389/fphar.2020.01004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 2021;17:81-97. [PMID: 33318665 DOI: 10.1038/s41584-020-00540-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. Ther Drug Monit 2017;39:364-9. [PMID: 28700520 DOI: 10.1097/FTD.0000000000000421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Aoyama M, Mano Y. Application of an electrochemiluminescence assay for quantification of E6011, an antifractalkine monoclonal antibody, to pharmacokinetic studies in monkeys and humans. J Clin Lab Anal 2019;33:e22625. [PMID: 30030862 DOI: 10.1002/jcla.22625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
58 Sáez Belló M, Llopis Salvia P, Alegre Sancho JJ, Paredes Arquiola JM, Asencio Muñoz MDC, Climente Martí M. Utilidad de las concentraciones séricas de adalimumab como predictores de adherencia al tratamiento. Reumatología Clínica 2020;16:32-7. [DOI: 10.1016/j.reuma.2018.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Akpalu DE, Frederick B, Nnane IP, Yao Z, Shen F, Ort T, Fink D, Dogmanits S, Raible D, Sharma A, Xu Z. Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects. J Clin Pharmacol 2019;59:968-78. [PMID: 30776134 DOI: 10.1002/jcph.1393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
60 Bejan‐angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Mammou S, Paintaud G, Mulleman D. Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. Arthritis & Rheumatology 2016;69:108-13. [DOI: 10.1002/art.39841] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
61 Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Ther Drug Monit 2017;39:350-5. [PMID: 28328761 DOI: 10.1097/FTD.0000000000000393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Reijers JA, van Donge T, Schepers FM, Burggraaf J, Stevens J. Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol 2016;72:1343-52. [PMID: 27515979 DOI: 10.1007/s00228-016-2101-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
63 Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clin Pharmacokinet 2019;58:169-87. [PMID: 29802542 DOI: 10.1007/s40262-018-0680-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]